Biological Background of GRIN3B

The GRIN3B gene encodes the GluN3B subunit, one of two glycine-binding regulatory subunits (GluN3A and GluN3B) of N-methyl-D-aspartate (NMDA) receptors. NMDA receptors are ionotropic glutamate receptors critical for synaptic transmission, learning, memory, and neurodevelopment. Unlike the obligatory GluN1 and the conventional GluN2 subunits, GluN3 subunits exert an inhibitory modulatory role when incorporated into the receptor complex, reducing calcium permeability and altering the pharmacological profile of the channel.

GluN3B is expressed predominantly in neurons of the peripheral and central nervous systems, with expression patterns that shift during postnatal development. Research involving recombinant GRIN3B protein supports investigation of receptor assembly, subunit–subunit interactions, drug binding studies, and biochemical characterization of this underexplored receptor subunit. Dysregulation of NMDA receptor function, including contributions from GluN3 subunits, has been associated with neurological and psychiatric conditions, making GRIN3B a relevant target in translational neuroscience research.

Reconstitution and Preparation Protocol

Follow the steps below to reconstitute and prepare Recombinant Human GRIN3B Protein (rp369994) for experimental use:

1. Equilibrate the vial: Allow the lyophilized protein vial to equilibrate to room temperature for 10–15 minutes before opening to minimize condensation-related degradation.
2. Centrifuge the vial: Briefly centrifuge the sealed vial (e.g., 10 seconds at low speed) to consolidate any protein that may have accumulated on the cap or sides.
3. Reconstitute with appropriate buffer: Add sterile, ultrapure water or the manufacturer-recommended reconstitution buffer (typically phosphate-buffered saline, pH 7.2–7.4, with a carrier protein such as 0.1% BSA if required for stability) dropwise to achieve the desired working concentration. Gently pipette to mix; do not vortex vigorously, as this may denature the protein.
4. Allow complete dissolution: Incubate the reconstituted solution on ice or at 2–8 °C for 5–10 minutes with gentle swirling to ensure complete dissolution.
5. Aliquot immediately: Prepare single-use aliquots to avoid repeated freeze-thaw cycles, which degrade protein activity and integrity.

Note: Specific reconstitution volume and buffer composition should be confirmed against the certificate of analysis (CoA) supplied with the product lot. Contact Aladdin Scientific technical support for lot-specific recommendations.

Storage, Stability, and Shipping Guidelines

Proper storage is essential to maintain the biological activity and structural integrity of Recombinant Human GRIN3B Protein.

• Short-term storage (up to 1 week): Store reconstituted protein at 2–8 °C. Addition of a carrier protein (e.g., 0.1% BSA) may extend short-term stability.
• Long-term storage: Store lyophilized or aliquoted reconstituted protein at -80 °C. Properly stored lyophilized protein typically retains activity for 12 months or more from the date of manufacture.
• Avoid freeze-thaw cycles: Each freeze-thaw cycle risks protein aggregation, loss of activity, and degradation. Pre-aliquot into volumes consistent with single experimental use.
• Do not store at -20 °C (frost-free freezers): Frost-free appliances undergo repeated temperature cycling that accelerates protein degradation.
• Shipping: The product is shipped on dry ice or with cold packs according to carrier stability requirements. Upon receipt, inspect the vial immediately and store as directed.

Always consult the product-specific CoA and datasheet for confirmed stability data for each manufacturing lot.

Experimental Applications and Usage Tips

Recombinant Human GRIN3B Protein (rp369994) is suitable for a range of in vitro biochemical and cell-based research applications, including but not limited to:

• Protein–protein interaction studies: Use in pull-down assays or co-immunoprecipitation experiments to identify GluN3B binding partners or to map interaction domains within the NMDA receptor complex.
• Biochemical characterization: Employ in SDS-PAGE, Western blotting, or ELISA-based assays for antibody validation and receptor subunit characterization.
• Drug screening and binding assays: Screen small molecules or peptide libraries for binding to the GluN3B subunit as part of NMDA receptor-targeted drug discovery programs.
• Structural studies: Use as a reference standard or antigen in structural biology pipelines (e.g., cryo-EM sample preparation, X-ray crystallography).
• Cell-free functional assays: Apply in reconstitution experiments studying receptor assembly mechanisms.

Usage tips:

• Determine optimal working concentration empirically for each application, as optimal concentrations vary by assay type.
• Include appropriate positive and negative controls in every experiment.
• Pre-clear lysates before use in interaction assays to reduce non-specific background.
• For antibody validation, run alongside endogenous protein lysates from GRIN3B-expressing neural tissues.

Quality Control and Troubleshooting

Ensuring experimental reproducibility with recombinant proteins requires attention to quality control at each step.

Quality Control Checks

• Purity verification: Confirm protein purity by running an SDS-PAGE gel and comparing to the CoA-stated purity specification. A single prominent band at the expected molecular weight confirms acceptable purity.
• Activity confirmation: Where functional assay data are available on the CoA, replicate the assay conditions at first use to confirm lot activity.
• Concentration determination: Measure protein concentration by BCA or Bradford assay after reconstitution to confirm the working stock concentration.

Common Issues and Solutions

• Protein aggregation: If cloudiness or precipitation is observed after reconstitution, centrifuge at low speed (e.g., 500–1000 × g, 5 minutes, 4 °C) and use the supernatant. Aggregation may also indicate excessive freeze-thaw cycles or incorrect buffer conditions.
• Loss of activity: Confirm storage conditions and number of freeze-thaw cycles. If activity is lower than expected, prepare a fresh aliquot from -80 °C stock.
• Unexpected bands on Western blot: Protein degradation bands may appear if the protein has been improperly stored or subjected to multiple freeze-thaw cycles. Use fresh material and include protease inhibitors in working buffers where appropriate.
• Non-specific binding in interaction assays: Pre-block surfaces with BSA or equivalent and include irrelevant recombinant protein controls.

For persistent technical issues, contact Aladdin Scientific technical support with your lot number and CoA details.